Patents Issued in March 17, 2020
  • Patent number: 10590374
    Abstract: Described herein is an improved automatic bioreactor system utilizing a multi-tray or multi-plate cell culture vessel for cultivating adherent cells.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: March 17, 2020
    Inventors: Timothy Ray Ho, Lewis Ho
  • Patent number: 10590375
    Abstract: The present disclosure relates to methods for control of cell growth rates where cell growth is measured in situ. The methods are applicable to bacterial cells, mammalian cells, non-mammalian eukaryotic cells, plant cells, yeast cells, fungi, and archea.
    Type: Grant
    Filed: August 27, 2019
    Date of Patent: March 17, 2020
    Assignee: Inscripta, Inc.
    Inventors: Don Masquelier, Phillip Belgrader
  • Patent number: 10590376
    Abstract: A system and method for conditioning a tissue are provided. The system includes a substrate, a plurality of microwells formed in the substrate, and a microsphere associated with each of the plurality of microwells. The system also includes a pair of flexible pillars within each of the plurality of microwells. Each flexible pillar includes a first end bonded to a respective microwell and at least one flexible pillar has a second end bonded to the microsphere. The flexible pillars are configured to deflect when exposed to a magnetic field to controllably stretch microtissue spanning the flexible pillars.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: March 17, 2020
    Assignee: The Johns Hopkins University
    Inventors: Daniel H. Reich, Fan Xu, Ruogang Zhao, Alan S. Liu, Tristin Metz, Yu Shi
  • Patent number: 10590377
    Abstract: A multi-function cooling and thermo-sensitive rack includes horizontal bars, a base, positioning holes, connectors, a lateral frame, connecting holes, a temperature-displaying prompter, and N temperature sensors. The lateral frame and the base are connected through the connectors. The lateral frame and the base have their surfaces facing each other symmetrically provided with plural connecting holes thereon. The horizontal bars have two ends thereof received in the corresponding symmetrical connecting holes. The positioning holes are distributed over the surface of the base. The N temperature sensors have output ends thereof for outputting sensing signals connected with input ends of the temperature-displaying prompter for inputting the N temperature-sensing signals. The present invention is applied to apparatuses used in microbiology experiment.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: March 17, 2020
    Assignee: HEBEI UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Xiaohui Zhou, Le Xu, Jun Liu, Hao Liu
  • Patent number: 10590378
    Abstract: A cell separation chip for separating cells from a solution containing the cells includes an upper plate, a membrane positioned on a predetermined region of the upper plate, and an absorption device positioned at a lower end of the upper plate so as to absorb a solution which has penetrated the membrane from the solution containing the cells. There is an effect of effectively collecting/separating only cells in a solution by absorbing the solution containing the cells without the need of applying and maintaining additional external voltage.
    Type: Grant
    Filed: April 11, 2016
    Date of Patent: March 17, 2020
    Assignee: FERRAMED INC.
    Inventor: Seyl Kim
  • Patent number: 10590379
    Abstract: A novel method of growing fungi is disclosed which uses an engineered artificial media and produces high density filamentous fungi biomats that can be harvested with a minimum of processing and from which fungal products such as antibiotics, proteins, and lipids can be isolated, the method resulting in lowered fungus cultivation costs for energy usage, oxygenation, water usage and waste stream production.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: March 17, 2020
    Assignee: Sustainable Bioproducts, Inc.
    Inventors: Mark A. Kozubal, Richard E. Macur, Yuval C. Avniel
  • Patent number: 10590380
    Abstract: The present invention provides a culture method of cells and/or tissues including culturing cells and/or tissues in a suspended state by using a medium composition wherein indeterminate structures are formed in a liquid medium, the structures are uniformly dispersed in the solution and substantially retain the cells and/or tissues without substantially increasing the viscosity of the solution, thus affording an effect of preventing sedimentation thereof, and the like.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: March 17, 2020
    Assignees: Nissan Chemical Industries, Ltd., Kyoto University
    Inventors: Taito Nishino, Tatsuro Kanaki, Ayako Otani, Koichiro Saruhashi, Misayo Tomura, Takehisa Iwama, Masato Horikawa, Norio Nakatsuji, Tomomi Otsuji
  • Patent number: 10590381
    Abstract: The present invention provides improved compositions and methods for the collection of stem cells from an organ, e.g., placenta. The invention provides a stem cell collection composition comprising an apoptosis inhibitor and, optionally, an enzyme such as a protease or mucolytic enzyme, vasodilator, necrosis inhibitor, oxygen-carrying perfluorocarbon, or an organ preserving compound. The invention provides methods of using the stem cell collection composition to collect stem cells and to preserve populations of stem cells.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: March 17, 2020
    Assignee: Celularity, Inc.
    Inventors: James W. Edinger, Mohammad Heidaran, Wolfgang Hofgartner
  • Patent number: 10590382
    Abstract: The present invention is of methods of establishing and propagating human embryonic stem cell lines using feeder cells-free, xeno-free culture systems and stem cells which are capable of being maintained in an undifferentiated, pluripotent and proliferative state in culture which is free of xeno contaminants and feeder cells.
    Type: Grant
    Filed: September 3, 2018
    Date of Patent: March 17, 2020
    Assignee: Technion Research & Development Foundation Limited
    Inventors: Michal Amit, Joseph Itskovitz-Eldor
  • Patent number: 10590383
    Abstract: Methods are provided, in some aspects, for differentiating pluripotent cells into midbrain dopaminergic (DA) neurons using a mono-SMAD inhibition or inhibition of SMAD signaling with only one SMAD inhibitor. In some embodiments, mono-SMAD inhibition utilizes a single inhibitor of bone morphogenic protein (BMP) for differentiating pluripotent cells into midbrain DA neurons.
    Type: Grant
    Filed: August 16, 2017
    Date of Patent: March 17, 2020
    Assignee: FUJIFILM Cellular Dynamics, Inc.
    Inventors: Christopher W. McMahon, Lauren E. Little, Wen Bo Wang, Nathaniel A. Elliott
  • Patent number: 10590384
    Abstract: The present disclosure relates to luterial, which is a mitochondrial-like unidentified nano-sized particle derived from a body fluid, and to a method for isolating the same.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: March 17, 2020
    Assignee: LUTERION CO., LTD.
    Inventors: Won Cheol Choi, Young Ah Kwon, Suk Hoon Choi, Chang Hoon Choi
  • Patent number: 10590385
    Abstract: A method for producing natural killer cells is disclosed. The method comprises isolating peripheral blood mononuclear cells (PBMCs) from a blood sample; isolating at least one of CD56+ cells and/or CD3?/CD56+ cells from the PBMCs; and co-culturing the at least one of CD56+ cells and/or CD3?/CD56+ cells with a combination of feeder cells in the presence of a cytokine. A composition for treating cancer is also disclosed. The composition comprises the CD56+ natural killer cells produced by the disclosed method and a cytokine.
    Type: Grant
    Filed: July 26, 2019
    Date of Patent: March 17, 2020
    Assignee: NKMAX CO., LTD.
    Inventors: Sang Woo Park, Yong Man Kim, Jae Seob Jung, Yong-Hee Rhee
  • Patent number: 10590386
    Abstract: The present invention discloses novel compositions and methods for enhancing cardiac differentiation efficiency of stem cells or promoting ventricular and atrial cardiomyocytes formation from stem cells. The present invention also discloses the atrial and ventricular cardiomyocytes formed from the stem cells, and the uses of the cardiomyocytes for repairing cardiac injuries and screening for new medicaments for treating cardiac injuries.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: March 17, 2020
    Assignee: INSITUTE OF BIOPHYSICS, CHINESE ACADEMY OF SCIENCES
    Inventor: Yue Ma
  • Patent number: 10590387
    Abstract: Provided herein are isolated CD133+ cells, such as human CD133+ cells, that have been expanded in culture and populations of isolated CD133+ cells that have been expanded in culture. The cells express transcription factors, growth factors, or a combination thereof, at altered levels compared to a naturally occurring CD133+ cell. Also provided are methods, including methods for expanding CD133+ cells and methods for using CD133+ cells.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: March 17, 2020
    Assignee: The Board of Regents of The University of Texas System
    Inventors: Larry Denner, Randall J. Urban, Yvonne Bodenburg
  • Patent number: 10590388
    Abstract: The present invention relates to a method for culturing bone marrow cells, in which bone marrow cells are applied to a porous polyimide film and cultured. Moreover, the present invention relates to a porous polyimide film for healing a bone injury site.
    Type: Grant
    Filed: January 26, 2016
    Date of Patent: March 17, 2020
    Assignees: UBE INDUSTRIES, LTD., KURUME UNIVERSITY
    Inventors: Keisuke Ohta, Shingo Hirashima, Masahiko Hagihara, Motohisa Shimizu
  • Patent number: 10590389
    Abstract: The present invention provides an endodermal cell production method that can induce differentiation of pluripotent cells into endodermal cells even when the pluripotent cells are dispersed and can achieve improved endodermal cell production efficiency. The endodermal cell production method according to the present invention is a method for producing endodermal cells by inducing differentiation of pluripotent cells into the endodermal cells, including the step of: inducing differentiation of the pluripotent cells into the endodermal cells in the presence of an endodermal cell inducing factor. In the induction step, the cell density of the pluripotent cells at the start of the induction preferably is from 0.5×104 to 2×104 cells/cm2.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: March 17, 2020
    Assignee: Kyoto University
    Inventors: Kenichiro Kamei, Momoko Honda
  • Patent number: 10590390
    Abstract: The present invention relates to a method for preparing highly pure pancreatic progenitor cells by using pluripotent stem cells such as ES cells or iPS cells as a source, inducing their differentiation into pancreatic progenitor cells, and culturing and proliferating the pancreatic progenitor cells. Specifically, the present invention relates to a method for proliferation of pancreatic progenitor cells, comprising the step of culturing the pancreatic progenitor cells in a medium containing (i) an EGF signal transduction activator and/or an FGF signal transduction activator and (ii) a ROCK inhibitor.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: March 17, 2020
    Assignee: Takeda Pharmaceutical Company Limited
    Inventor: Yuya Kunisada
  • Patent number: 10590391
    Abstract: Provided herein are isolated populations of kidney cells harvested from differentiated cells of the kidney, wherein the cells have been expanded in vitro. The kidney cells preferably produce erythropoietin (EPO). The kidney cells may also be selected based upon EPO production. Methods of producing an isolated population of EPO producing cells are also provided, and methods of treating a kidney disease resulting in decreased EPO production in a patient in need thereof are provided, including administering the population to the patient, whereby the cells express EPO in vivo in an oxygen tension-dependent manner.
    Type: Grant
    Filed: November 13, 2009
    Date of Patent: March 17, 2020
    Assignee: WAKE FOREST UNIVERSITY HEALTH SCIENCES
    Inventors: Anthony Atala, James J. Yoo
  • Patent number: 10590392
    Abstract: The technology described herein relates to methods and kits for directed differentation of primordial NKX2-1+ lung progenitors along proximal differentiation pathways into functional airway epithelial cells and airway organoids (“bronchospheres”) or along distal lineage pathways using modulation of Wnt signaling. Other aspects relate cell lines, methods, assays and kits comprising airway epithelial cells, and assays for diagnosing a disease that affects swelling of the bronchospheres, and/or for assessing genetic lesions and/or drugs for treating the the disease, where the disease is cystic fibrosis. Other aspects relate to personalized medicine and methods of treatment of cystic fibrosis using the airway epithelial cells.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: March 17, 2020
    Assignee: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Darrell N. Kotton, Katherine B. McCauley, Finn Hawkins
  • Patent number: 10590393
    Abstract: In one embodiment, the present invention is a method of creating a fully-human blood-brain barrier (BBB) model, comprising the steps of (a) obtaining a mixture of neural cells and brain microvascular endothelial cells (BMECs), wherein the neural cells and BMECs that comprise the mixture were produced from the differentiation of human pluripotent stem cells (hPSCs); (b) purifying BMECs from the mixture of neural cells and BMECs of step (a); and (c) co-culturing the purified BMECs with a cell type selected from the group consisting of pericytes, astrocytes and differentiated neural progenitor cells (NPCs), wherein a blood brain barrier model is created.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: March 17, 2020
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Eric V. Shusta, Sean P. Palecek, Ethan S. Lippmann, Samira M. Azarin
  • Patent number: 10590394
    Abstract: A method of non-covalently loading a plant picornavirus is described. The method includes contacting a plant picornavirus in solution with a molar excess of a cargo molecule to load the plant picornavirus with the cargo molecule, and then purifying the loaded plant picornavirus. Examples of cargo molecules include imaging agents, antitumor agents, and antiviral agents. Loaded plant picornaviruses prepared in this manner can be used to delivering cargo molecule to cells.
    Type: Grant
    Filed: February 18, 2014
    Date of Patent: March 17, 2020
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Nicole Steinmetz, Daniel Popkin
  • Patent number: 10590395
    Abstract: Provided is a mutant protein obtained by mutating a specific amino acid residue of HMGR, a rate-limiting enzyme of isoprene monomer biosynthesis in the polyisoprenoid biosynthesis pathway. The present invention relates to a mutant protein, wherein at least one amino acid residue selected from the group consisting of amino acid residues at positions 91, 225, 257, 287, 339, 411, 470, 509 and 574 of the Arabidopsis thaliana 3-hydroxy-3-methylglutaryl CoA reductase shown by SEQ ID NO:1 and amino acid residues at positions corresponding to the foregoing in 3-hydroxy-3-methylglutaryl CoA reductase is deleted or replaced with another amino acid residue.
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: March 17, 2020
    Assignees: OSAKA UNIVERSITY, SUMITOMO RUBBER INDUSTRIES, LTD.
    Inventors: Keiko Suzuki, Jekson Robertlee, Toshiya Muranaka, Keiji Takagi, Yukino Inoue, Kazuhisa Fushihara
  • Patent number: 10590396
    Abstract: The disclosure relates to engineered ketoreductase polypeptides and processes of using the polypeptides for production of phenylephrine.
    Type: Grant
    Filed: June 11, 2019
    Date of Patent: March 17, 2020
    Assignee: Codexis, Inc.
    Inventors: Oscar Alvizo, Steven J. Collier, Hans-Georg Joerg Hennemann, Seong Ho Oh, Wenjuan Zha
  • Patent number: 10590397
    Abstract: Compositions and methods for increasing resistance to Fusarium infection in plants are provided herein. Polynucleotides, polypeptides, and expression constructs for expressing mutant UDP-glycosyltransferase proteins, plants comprising the polynucleotides, polypeptides or expression constructs, and methods of producing transgenic plants are also provided.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: March 17, 2020
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Ivan Rayment, Karl Wetterhorn
  • Patent number: 10590398
    Abstract: Phototropin is a blue light receptor, which mediates a variety of blue-light elicited physiological processes in plants and algae. In higher plants these processes include phototropism, chloroplast movement and stomatal opening. In the green alga Chlamydomonas reinhardtii, phototropin plays a vital role in progression of the sexual life cycle and in the control of the eye spot size and light sensitivity Phototropin is also involved in blue-light mediated changes in the synthesis of chlorophylls, carotenoids, chlorophyll binding proteins. We compared the transcriptome of phototropin knock out (PHOT KO) mutant and wild-type parent to analyze differences in gene expression in high light grown cultures (500 ?mol photons m?2 s?1). Our results indicate the up-regulation of genes involved in photosynthetic electron transport chain, carbon fixation pathway, starch, lipid, and cell cycle control genes.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: March 17, 2020
    Assignees: NMC, INC., LOS ALAMOS NATIONAL SECURITY, LLC
    Inventors: Sangeeta Negi, Richard Thomas Sayre, Shawn Robert Starkenburg
  • Patent number: 10590399
    Abstract: A DNA polymerase mutant comprising a Taq DNA polymerase amino acid sequence with a mutation at one or more of the following selected amino acid positions: E189K, E230K, E507K, H28R, L30R, G38R, F73V, H75R, E76A, E76G, E76K, E90K, K206R, E315K, A348V, L351F, A439T, D452N, G504S, E507A, D551N, L552R, I553V, D578N, H676R, Q680R, D732G, E734G, E734K, F749V; wherein the polymerase mutant exhibits relative to wild-type DNA polymerase increased polymerase speed, increased affinity to DNA substrate and/or increased resistance to a DNA polymerase inhibitor; and wherein, when the mutation is E507K in combination with two or more further mutations or the mutation is Q680R in combination with four or more further mutations, at least one of the further mutations is at one of the selected amino acid positions; and when the mutation is I553V, this is not in combination with D551S.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: March 17, 2020
    Assignee: Thermo Fisher Scientific Baltics UAB
    Inventors: Remigijus Skirgaila, Agne Tubelevic̆iūtē, Renata Rims̆eliēnē, Sigitas Burinskas
  • Patent number: 10590400
    Abstract: Disclosed are mutant DNA polymerases having increased 3?-mismatch discrimination relative to a corresponding, unmodified polymerase. The mutant polymerases are useful in a variety of disclosed primer extension methods. Also disclosed are related compositions, including recombinant nucleic acids, vectors, and host cells, which are useful, e.g., for production of the mutant DNA polymerases.
    Type: Grant
    Filed: January 4, 2018
    Date of Patent: March 17, 2020
    Assignee: Roch Molecular Systems, Inc.
    Inventors: Keith Bauer, Fred Reichert, Thomas W. Myers
  • Patent number: 10590401
    Abstract: The present invention relates to novel esterase, more particularly to esterase variants having improved activity compared to the esterase of SEQ ID NO: 1 and the uses thereof for degrading polyester containing material, such as plastic products. The esterases of the invention are particularly suited to degrade polyethylene terephthalate, and material containing polyethylene terephthalate.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: March 17, 2020
    Assignee: CARBIOS
    Inventors: Vincent Tournier, Helene Texier, Marie-Laure Desrousseaux, Christopher Topham, Isabelle Andre, Sophie Barbe, Sophie Duquesne, Alain Marty
  • Patent number: 10590402
    Abstract: Disclosed is a combination of two or more lipase enzymes, and its use for treating a lipid digestion deficiency and/or a digestive disorder. At least one lipase enzyme has a pH optimum at an acidic pH value, while at least one other lipase enzyme has a pH optimum at an alkalic pH value.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: March 17, 2020
    Assignee: CILIAN AG
    Inventors: Marcus Wolf William Hartmann, Ingo Aldag
  • Patent number: 10590403
    Abstract: Acinetobacter lysin polypeptides and variants peptides with killing activity against gram negative bacteria. Methods for treating bacterial infections or bacterial colonization using Acinetobacter lysin polypeptides.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: March 17, 2020
    Assignee: The Rockefeller University
    Inventors: Vincent Fischetti, Raymond Schuch, Rolf Lood, Benjamin Winer
  • Patent number: 10590404
    Abstract: The present invention pertains to the field of amylases with reduced disposition to form deamidation products, particularly alpha-amylases, and compositions comprising such amylases. Also described are means and methods for producing such amylases, and uses of amylases and amylase-comprising compositions, for example for cleaning starch-containing stains, textile desizing, starch liquefaction and saccharification, baking and brewing. The invention also discloses means for increasing amylase purity during fermentation, formulation and storage of amylase or amylase-containing formulations.
    Type: Grant
    Filed: April 15, 2015
    Date of Patent: March 17, 2020
    Assignee: BASF SE
    Inventors: Stefan Jenewein, Stefan Niedermaier
  • Patent number: 10590405
    Abstract: A process for producing blood coagulation Factor VII in 3 human cell lines (HepG2, Sk-Hep, HKB-11) and to select the best recombinant protein producer is described. The murine line BHK-21 was used as control. The data allow to assert that the system used to modify cell lines was efficient, so that all the cells were satisfactorily modified, and produced the protein of interest of stable form. In addition, when comparing the murine line BHK-21 with the human cells (HepG2, Sk-Hep-1 and HKB-11), the latter showed to be able to produce rFVII more efficiently, which allows to conclude that human cell lines are a great alternative for the production of recombinant blood coagulation factors.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: March 17, 2020
    Assignee: FUNDAÇÃO HEMOCENTRO DE RIBEIRÃO PRETO—FUNDHERP
    Inventors: Dimas Tadeu Covas, Marcela Cristina Corrêa de Freitas, Virginia Picanço e Castro, Kamilla Swiech
  • Patent number: 10590406
    Abstract: The invention provides a recombinant, carboxydotrophic Clostridium bacterium that expresses one or more of pyruvate:ferredoxin oxidoreductase (EC 1.2.7.1), acetolactate synthase (EC 2.2.1.6), and acetolactate decarboxylase (EC 4.1.1.5). The invention further provides a method of producing a fermentation product by fermenting the recombinant bacterium in the presence of a gaseous substrate comprising CO to produce one or more of ethanol, butanol, isopropanol, isobutanol, higher alcohols, butanediol, 2,3-butanediol, succinate, isoprenoids, fatty acids, biopolymers, and mixtures thereof.
    Type: Grant
    Filed: December 7, 2015
    Date of Patent: March 17, 2020
    Assignee: LANZATECH NEW ZEALAND LIMITED
    Inventors: Michael Koepke, Alexander Paul Mueller, Loan Phuong Tran
  • Patent number: 10590407
    Abstract: The present invention is directed to enzymes having Asx-specific ligase and cyclase activity and to nucleic acids encoding those as well as methods of the manufacture of said enzymes. Further encompassed are methods and uses of these enzymes.
    Type: Grant
    Filed: March 24, 2015
    Date of Patent: March 17, 2020
    Assignee: Nanyang Technological University
    Inventors: Kien Truc Giang Nguyen, James P. Tam
  • Patent number: 10590408
    Abstract: The present invention relates to biomolecule stabilization to provide biomolecules, such as sensitive polymerases, in a convenient ready-to-go format. The invention provides a method and composition in which non-ionic surfactant or detergents of the polyoxyethylene cetyl ether family are used, preferably a Brij reagent or a combination of Brij reagents.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: March 17, 2020
    Assignee: GE Healthcare UK Limited
    Inventors: Peter James Tatnell, Elizabeth Mary Ashman
  • Patent number: 10590409
    Abstract: A method and a device are provided for facilitating the disaggregation of a plurality of solid phase substrate as the plurality of solid phase substrate are transferred from a first location to a second location. A plurality of solid phase substrate are deposited at the first location and a plurality of particles are added to the plurality of solid phase substrate. A force is generated to draw the plurality of solid phase substrate from the first location to a second location. The plurality of particles causes clumps of the plurality of solid phase substrate to break apart as the plurality of solid phase substrate are moved in response to the force.
    Type: Grant
    Filed: December 6, 2016
    Date of Patent: March 17, 2020
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: David J. Beebe, David J. Guckenberger, Jr., Hannah M. Pezzi
  • Patent number: 10590410
    Abstract: Methods for processing polynucleotide-containing biological samples, and materials for capturing polynucleotide molecules such as RNA and/or DNA from such samples are provided. The RNA and/or DNA is captured by polyamindoamine (PAMAM (Generation 0)) bound to a surface, such as the surface of magnetic particles. The methods and materials have high efficiency of binding RNA and of DNA, and of release, and thereby permit quantitative determinations. The binding particles can be coated with PAMAM (Generation 0) dendrimer which is amide-bonded to the binding particles, wherein at least a portion of the nucleic acids in the biological sample become reversibly bonded to the binding particles.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: March 17, 2020
    Assignee: HANDYLAB, INC.
    Inventors: Sundaresh N. Brahmasandra, Elizabeth Craig
  • Patent number: 10590411
    Abstract: The invention relates to methods for the detection of a specific sequence of RNA in a cell or tissue sample. The invention also relates to methods to enzymatically manipulate the RNA in a crude cell lysate in a number of applications.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: March 17, 2020
    Assignee: APPLIED BIOSYSTEMS, LLC
    Inventors: Brittan Pasloske, Quoc Hoang
  • Patent number: 10590412
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the amount or activity of a target nucleic acid. In certain embodiments, the amount or activity of a target nucleic acid is modulated through nonsense mediated decay.
    Type: Grant
    Filed: April 21, 2014
    Date of Patent: March 17, 2020
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Amanda Ward, Frank Rigo
  • Patent number: 10590413
    Abstract: The present invention relates to chirally controlled oligonucleotides, chirally controlled oligonucleotide compositions, and the method of making and using the same. The invention specifically encompasses the identification of the source of certain problems with prior methodologies for preparing chiral oligonucleotides, including problems that prohibit preparation of fully chirally controlled compositions, particularly compositions comprising a plurality of oligonucleotide types. In some embodiments, the present invention provides chirally controlled oligonucleotide compositions. In some embodiments, the present invention provides methods of making chirally controlled oligonucleotides and chirally controlled oligonucleotide compositions.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: March 17, 2020
    Assignee: WAVE LIFE SCIENCES LTD.
    Inventors: David Charles Donnell Butler, Naoki Iwamoto, Meena, Nenad Svrzikapa, Gregory L. Verdine, Ivan Zlatev
  • Patent number: 10590414
    Abstract: The disclosed subject matter relates to brush polymer-oligonucleotide conjugates comprising oligonucleotides covalently attached to the backbone of a non-cationic, sterically congested brush polymer and the use of such polymer-oligonucleotide conjugates in antisense gene regulation and as diagnostic agents.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: March 17, 2020
    Assignee: NORTHEASTERN UNIVERSITY
    Inventors: Ke Zhang, Xueguang Lu
  • Patent number: 10590415
    Abstract: The present disclosure provides engineered Class 2 CRISPR-Cas-associated discontinuous first-stem nucleic-acid targeting nucleic acids, nucleoprotein complexes comprising these nucleic acids, and compositions thereof. Nucleic acid sequences encoding the Class 2 CRISPR-Cas-associated discontinuous first-stem nucleic-acid targeting nucleic acids, as well as expression cassettes, vectors and cells comprising such nucleic acid sequences, are described. Also, methods are disclosed for making and using the Class 2 CRISPR-Cas-associated discontinuous first-stem nucleic-acid targeting nucleic acids, nucleoprotein complexes comprising such nucleic acids, and compositions thereof.
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: March 17, 2020
    Assignee: Ceribou Biosciences, Inc.
    Inventors: Paul Daniel Donohoue, Andrew Paul May
  • Patent number: 10590416
    Abstract: Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of an alpha-ENaC (SCNN1A) gene. The alpha-ENaC RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of an alpha-ENaC gene. Pharmaceutical compositions that include one or more alpha-ENaC RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described alpha-ENaC RNAi agents to epithelial cells, such as pulmonary epithelial cells, in vivo, provides for inhibition of alpha-ENaC gene expression and a reduction in ENaC activity, which can provide a therapeutic benefit to subjects, including human subjects.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: March 17, 2020
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Zhen Li, Rui Zhu, Tao Pei, Anthony Nicholas, Erik W Bush
  • Patent number: 10590417
    Abstract: Disclosed herein are compositions comprising extracellular vesicles, such as exosomes, displaying an RNA nanoparticle on its surface. The RNA nanoparticle can target the extracellular vesicle to a given cell via a targeting moiety. The extracellular vesicle can also comprise a functional moiety, which can be used in treatment or diagnostics.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: March 17, 2020
    Assignee: Ohio State Innovation Foundation
    Inventors: Peixuan Guo, Fengmei Pi, Hui Li, Shaoying Wang
  • Patent number: 10590418
    Abstract: Methods and compositions are provided for modulating, e.g., reducing, viral coding sequence expression in mammals and mammalian cells. In the subject methods, an effective amount of an RNAi agent, e.g., an interfering ribonucleic acid (such as an siRNA or shRNA) or a transcription template thereof, e.g., a DNA encoding an shRNA, is introduced into a target cell, e.g., by being administered to a mammal that includes the target cell, e.g., via a hydrodynamic administration protocol. Also provided are RNAi agent pharmaceutical preparations for use in the subject methods. The subject methods and compositions find use in a variety of different applications, including academic and therapeutic applications.
    Type: Grant
    Filed: September 27, 2002
    Date of Patent: March 17, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Mark A. Kay, Anton McCaffrey
  • Patent number: 10590419
    Abstract: The invention relates to compostions and methods for promoting cellular proliferation and de-differentiation of cells into stem cells to foster tissue regeneration. Specifically, the invention relates to transiently administering a microRNA (miR) or its mimic for promoting cardiomyocyte proliferation and cardiac regeneration.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: March 17, 2020
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventor: Edward E. Morrisey
  • Patent number: 10590420
    Abstract: The invention relates to a method for the treatment of amyotrophic lateral sclerosis (ALS). Specifically, the invention implements the use of an antisense sequence adapted to affect alternative splicing in a human SOD1 pre-mRNA, thereby leading to the destruction of the skipped m RNA by the cell machinery.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: March 17, 2020
    Assignees: ASSOCIATION INSTITUT DE MYOLOGIE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6)
    Inventors: Martine Barkats, Maria-Grazia Biferi, Thomas Voit
  • Patent number: 10590421
    Abstract: Described are methods for removing a proteolytic cleavage site, the HCHWA-D mutation or the amino acids encoded by a trinucleotide repeat expansion from a protein comprising providing a cell that expresses pre-mRNA encoding the protein with an anti-sense oligonucleotide that induces skipping of the exonic sequence that comprises the proteolytic cleavage site, HCHWA-D mutation or trinucleotide repeat expansion, respectively, the method further comprising allowing translation of mRNA produced from the pre-mRNA.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: March 17, 2020
    Assignee: Academisch Ziekenhuis Leiden H.O.D.N. LUMC
    Inventors: Wilhelmina M. C. van Roon-Mom, Melvin Maurice Evers, Barry Antonius Pepers, Annemieke Aartsma-Rus, Garrit-Jan Boudewijn Van Ommen
  • Patent number: 10590422
    Abstract: The present invention is directed to a method of treating cancer using interfering RNA duplexes to mediate gene silencing. The present invention is also directed to interfering RNA duplexes and vectors encoding such interfering RNA duplexes.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: March 17, 2020
    Assignee: PHYZAT BIOPHARMACEUTICALS, LDA.
    Inventor: Patricio Soares da Silva
  • Patent number: 10590423
    Abstract: In certain aspects, provided herein are RNA complexes that inhibit Myeloid differentiation primary response gene 88 (MyD88) and/or Toll-like receptor 3 (TLR3) and are useful in the treatment of age-related macular degeneration (AMD). In certain aspects, provided herein are pharmaceutical compositions comprising such RNA complexes and methods of using such RNA complexes and pharmaceutical compositions.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: March 17, 2020
    Assignee: OliX Pharmaceuticals, Inc.
    Inventors: Dong-ki Lee, Sun Woo Hong, Isu Hong, Jihye Hwang